This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Looking at the Proposed National Coverage Determination on Renal Denervation for Hypertension: Implications for Medtronic’s Symplicity Spyral™ and Otsuka’s Paradise™ Systems.

Ticker(s): MDT, OTSKF

Who's the expert?

Institution: University of Vermont Health

  • Interventional cardiologist at the University of Vermont Medical Center.
  • Performing 10+ Renal Denervation Procedures annually
  • Actively involved in clinical trials and database research focused on interventional cardiology and heart valve therapies.

Interview Questions
Q1.

How many renal denervation procedures do you perform annually?

Added By: nick_admin
Q2.

On a scale of 1–10, how big of a shift could CMS coverage for RDN represent for resistant hypertension treatment in the next 2–3 years?

Added By: nick_admin
Q3.

Once CMS finalizes national coverage, how quickly do you expect commercial insurers to follow with coverage decisions?

Added By: nick_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.